Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents		$ 66,824	$ 127,965
Prepaid expenses and other current assets		6,104	8,049
Current assets of discontinued operations		0	39,396
Total current assets		72,928	175,410
Property and equipment, net		12,566	17,614
Operating lease assets		82,910	90,417
Restricted cash		9,873	8,185
Restricted investments		0	1,401
Other non-current assets		465	2,187
Non-current assets of discontinued operations	[1]	0	63,386
Total assets		178,742	358,600
Current liabilities:
Accounts payable		8,254	3,641
Accrued expenses and other current liabilities		17,716	22,509
Accrued liabilities due to SPN - related party		30,517	0
Operating lease liabilities		8,346	5,587
Current liabilities of discontinued operations	[2]	0	66,922
Total current liabilities		64,833	98,659
Long term portion of note payable, net of discount		0	101,544
Operating lease liabilities, net of current portion		85,266	91,652
Accrued liabilities due to SPN, net of current portion - related party		2,941	0
Warrant liabilities		0	546
Other long-term liabilities		1,783	1,628
Non-current liabilities of discontinued operations		0	109,427
Total liabilities		154,823	403,456
Commitments and contingencies (Note 13)
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023		0	0
Common stock, $0.001 par value; 360,000,000 shares authorized at September 30, 2024 and 240,000,000 share authorized December 31, 2023; 170,200,253 and 135,041,467 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		170	135
Additional paid-in capital		986,211	933,244
Accumulated other comprehensive loss		0	0
Accumulated deficit		(962,462)	(978,235)
Total stockholders' equity (deficit)		23,919	(44,856)
Total liabilities and stockholders' equity (deficit)		$ 178,742	$ 358,600

[1] Includes $38,877 as of December 31, 2023 of milestones related to the construction of the Company's dedicated manufacturing suite at BacThera AG, or Bacthera.

[2] Includes related party amount of $35,783 at December 31, 2023.